Peter C. Taylor

United Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Collaborators (10)

Torkell Ellingsen

Gerd-Rüdiger Burmester

Senior Professor

Charité - Universitätsmedizin Berlin

Ernest Choy

Professor of Rheumatology

Cardiff University

UNITED KINGDOM

Zoltán Szekanecz

University of Debrecen

Tsutomu Takeuchi

Keio University School of Medicine

Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

Xenofon Baraliakos

vibeke strand

Adjunct Clinical Professor

Stanford University School of Medicine

UNITED STATES

Line Uhrenholt

Aalborg University

Axel Finckh

University Hospital of Geneva

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter C. Taylor

Research Interests

Explore related searches

Contact this professor

Articles (21)

Collaborators (10)

Torkell Ellingsen

Gerd-Rüdiger Burmester

Ernest Choy

Zoltán Szekanecz

Tsutomu Takeuchi

Roy Fleischmann

Xenofon Baraliakos

vibeke strand

Line Uhrenholt

Axel Finckh

Make your next move.

Peter C. Taylor

Research Interests

Explore related searches

Contact this professor

Articles (21)

Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study

Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

Towards better personalized care in rheumatoid arthritis

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials

Pain in the joints and beyond; the challenge of rheumatoid arthritis

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Collaborators (10)

Torkell Ellingsen

Gerd-Rüdiger Burmester

Ernest Choy

Zoltán Szekanecz

Tsutomu Takeuchi

Roy Fleischmann

Xenofon Baraliakos

vibeke strand

Line Uhrenholt

Axel Finckh

Make your next move.